Bortezomib
2023-358-02
Phase 2 small_molecule active
Quick answer
Bortezomib for Systemic Amyloidosis is a Phase 2 program (small_molecule) at Jin Lu, MD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jin Lu, MD
- Indication
- Systemic Amyloidosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active